Responsibilities

• Define and lead the integrated U.S. strategy across portfolio, pipeline, and strategic engagement for Hepatology/Immunology medicines.
• Ensure tight linkage between early asset strategy and in-market execution, connecting development decisions with customer engagement and insights.
• Serve as the voice of the U.S. commercial for Hepatology/Immunology across governance forums and enterprise decision-making bodies.
• Drive alignment across Brand, Medical, Market Access, R&D, and Commercial leadership where appropriate and applicable.
• Operates as the Marketing VP's primary strategic deputy for Hepatology/Immunology, holding functional decision-making authority over U.S. engagement investment priorities, external expert strategy, and the commercial input into pipeline decisions. Accountable for ensuring recommendations reaching VP and above are fully developed, compliant with all US Policies and SOPs, cross-functionally aligned, and commercially defensible
• Oversee development of integrated U.S. portfolio strategies across in-line and pipeline Hepatology/Immunology assets (Phase 2 through launch), ensuring alignment with brand strategy, commercial objectives, and medical priorities.
• Ensure delivery of robust U.S. market analyses, insights, and assumptions that inform stage-gate decisions, financial valuations, and investment prioritization.
• Lead lifecycle strategy, including indication prioritization, sequencing, and lifecycle extension opportunities, informed by insights from in-line brands, customer experience, and external experts.
• Embed payer, access, and value considerations early in development planning in partnership with Market Access, Health Outcomes, and Medical Affairs.
• Set the Hepatology/Immunology strategy for HCP and external expert engagement, ensuring alignment with portfolio and pipeline priorities.